Maladaptive activation of Nav1.9 channels by nitric oxide causes triptan-induced medication overuse headache.
Animals
Calcitonin Gene-Related Peptide
/ metabolism
Cell Degranulation
/ physiology
Cells, Cultured
Female
Headache Disorders, Secondary
/ chemically induced
Hyperalgesia
/ physiopathology
Male
Mast Cells
/ pathology
Mice
Mice, Inbred C57BL
Mice, Knockout
Migraine Disorders
/ pathology
NAV1.9 Voltage-Gated Sodium Channel
/ genetics
Neurons, Afferent
/ drug effects
Nitric Oxide
/ metabolism
Nociceptors
/ physiology
Pain
/ physiopathology
Prescription Drug Overuse
/ adverse effects
Tryptamines
/ adverse effects
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
18 09 2019
18 09 2019
Historique:
received:
04
12
2018
accepted:
26
08
2019
entrez:
20
9
2019
pubmed:
20
9
2019
medline:
4
1
2020
Statut:
epublish
Résumé
Medication-overuse headaches (MOH) occur with both over-the-counter and pain-relief medicines, including paracetamol, opioids and combination analgesics. The mechanisms that lead to MOH are still uncertain. Here, we show that abnormal activation of Nav1.9 channels by Nitric Oxide (NO) is responsible for MOH induced by triptan migraine medicine. Deletion of the Scn11a gene in MOH mice abrogates NO-mediated symptoms, including cephalic and extracephalic allodynia, photophobia and phonophobia. NO strongly activates Nav1.9 in dural afferent neurons from MOH but not normal mice. Abnormal activation of Nav1.9 triggers CGRP secretion, causing artery dilatation and degranulation of mast cells. In turn, released mast cell mediators potentiates Nav1.9 in meningeal nociceptors, exacerbating inflammation and pain signal. Analysis of signaling networks indicates that PKA is downregulated in trigeminal neurons from MOH mice, relieving its inhibitory action on NO-Nav1.9 coupling. Thus, anomalous activation of Nav1.9 channels by NO, as a result of chronic medication, promotes MOH.
Identifiants
pubmed: 31534133
doi: 10.1038/s41467-019-12197-3
pii: 10.1038/s41467-019-12197-3
pmc: PMC6751217
doi:
Substances chimiques
Calca protein, mouse
0
NAV1.9 Voltage-Gated Sodium Channel
0
Scn11a protein, mouse
0
Tryptamines
0
Nitric Oxide
31C4KY9ESH
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4253Commentaires et corrections
Type : ErratumIn
Références
Pain. 1980 Apr;8(2):253-259
pubmed: 7402688
J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):233-240
pubmed: 27503742
Cephalalgia. 2006 Sep;26(9):1106-14
pubmed: 16919061
Pain. 2010 Aug;150(2):222-224
pubmed: 20546999
Nat Genet. 2013 Nov;45(11):1399-404
pubmed: 24036948
Eur J Neurosci. 2001 Jun;13(11):2099-104
pubmed: 11422450
Brain. 2010 Aug;133(Pt 8):2475-88
pubmed: 20627971
Pain. 2011 Mar;152(3 Suppl):S2-S15
pubmed: 20961685
Ann Neurol. 2010 Mar;67(3):325-37
pubmed: 20373344
PLoS One. 2011;6(8):e23083
pubmed: 21857998
J Immunol. 2006 Nov 1;177(9):6422-32
pubmed: 17056574
Nat Rev Neurosci. 2015 Sep;16(9):511-9
pubmed: 26243570
Ann Neurol. 1990 Aug;28(2):183-7
pubmed: 1699472
Trends Pharmacol Sci. 2005 Feb;26(2):62-8
pubmed: 15681022
Cephalalgia. 2010 Mar;30(3):272-84
pubmed: 19614707
Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9382-7
pubmed: 15964986
Chem Immunol Allergy. 2012;98:196-221
pubmed: 22767065
Mol Psychiatry. 2002;7(10):1039-53
pubmed: 12476318
Neurosci Lett. 2009 Mar 6;452(1):28-32
pubmed: 19146922
J Pain Res. 2014 Jun 26;7:367-78
pubmed: 25061336
Cephalalgia. 2000 Dec;20(10):907-18
pubmed: 11304026
Pain. 2003 Dec;106(3):461-470
pubmed: 14659530
Pharmacol Ther. 2008 Nov;120(2):157-71
pubmed: 18789357
Brain Res Brain Res Rev. 2005 Jun;48(3):438-56
pubmed: 15914251
Mol Pain. 2015 Nov 25;11:72
pubmed: 26607325
J Physiol. 2003 Apr 15;548(Pt 2):373-82
pubmed: 12651922
Neuroscience. 2012 Oct 11;222:205-14
pubmed: 22800565
Curr Neurol Neurosci Rep. 2004 Mar;4(2):98-104
pubmed: 14984680
Am J Hum Genet. 2013 Nov 7;93(5):957-66
pubmed: 24207120
Neurobiol Dis. 2012 Jan;45(1):633-44
pubmed: 22033344
Pain. 2003 Jan;101(1-2):25-32
pubmed: 12507697
Cephalalgia. 2013 May;33(7):444-53
pubmed: 23431023
Brain. 2014 Jun;137(Pt 6):1627-42
pubmed: 24776970
Mol Cell Neurosci. 2004 May;26(1):123-34
pubmed: 15121184
EMBO J. 2018 Apr 13;37(8):
pubmed: 29459435
Cephalalgia. 2012 Aug;32(11):822-33
pubmed: 22718556
Cephalalgia. 2013 Jul;33(9):629-808
pubmed: 23771276
Mol Cell Neurosci. 2007 May;35(1):138-52
pubmed: 17363266
Lancet Neurol. 2013 May;12(5):454-61
pubmed: 23578775
Cell Rep. 2015 May 19;11(7):1067-78
pubmed: 25959819
Neuroscience. 2002;115(2):441-53
pubmed: 12421610
CNS Drugs. 2013 Dec;27(12):1049-68
pubmed: 24234657
Pain. 2013 Dec;154 Suppl 1:S44-53
pubmed: 23891892
Trends Neurosci. 2002 May;25(5):253-9
pubmed: 11972962
J Gen Physiol. 2008 Mar;131(3):211-25
pubmed: 18270172
J Neurosci. 2006 Dec 13;26(50):12852-60
pubmed: 17167076
Cephalalgia. 2014 Jul;34(8):594-604
pubmed: 24335852